{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:12:29Z","timestamp":1790190749650,"version":"4.1.0"},"reference-count":29,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,12,7]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The clinical characteristics of autoantibody-mediated autoimmune diseases are diverse. Yet, medical treatment and the associated complications are similar, that is, the occurrence of long-term side effects and the problem that a significant proportion of patients are non-responders. Therefore, new therapeutic options are needed. Bortezomib, a proteasome inhibitor, is effective in the treatment of multiple myeloma and data from experimental models and case reports suggest an effect in the treatment of autoantibody-mediated autoimmunity. In our study, we will determine the effect of bortezomib treatment on a shared surrogate parameter for clinical efficacy, namely change in autoantibody levels, which we chose as primary parameter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We designed a phase IIa trial with altogether n=18 treatment-refractory patients suffering from myasthenia gravis, systemic lupus erythematosus and rheumatoid arthritis that will be treated with bortezomib add-on to pre-existing therapy. Primary endpoint is the change in autoantibody levels 6 months after therapy. Secondary endpoints include concomitant medication, disease-specific clinical scores and measures of quality of life and activities of daily living.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Safety parameters include neurophysiological and clinical signs of peripheral neuropathy as well as potential central nervous system side effects determined by olfactory and neuropsychological testing. The study has been approved by the local ethical committee and first participants have already been enrolled. This proof of concept study will contribute to improve our understanding of plasma cell-specific treatment approaches by assessing its safety and efficacy in reducing serum levels of antibodies known to mediate autoimmune disorders.<\/jats:p>\n                    <jats:p>We plan to publish the final results of our study in a peer reviewed journal and to present our findings at international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT02102594\" ext-link-type=\"clintrialgov\">NCT02102594<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-024523","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T06:02:32Z","timestamp":1548741752000},"page":"e024523","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":47,"title":["Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02102594","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Siegfried","family":"Kohler","sequence":"first","affiliation":[{"name":"Department of Experimental Neurology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Department of Neurology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Neurocure Clincal Research Center, Charite Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3303-5819","authenticated-orcid":false,"given":"Stefanie","family":"M\u00e4rschenz","sequence":"additional","affiliation":[{"name":"Neurocure Clincal Research Center, Charite Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Grittner","sequence":"additional","affiliation":[{"name":"Institute of Biometry and Clinical Epidemiology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Hiepe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[{"name":"Department of Experimental Neurology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Department of Neurology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Neurocure Clincal Research Center, Charite Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"2025121408025630000_9.1.e024523.1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e328364c079"},{"key":"2025121408025630000_9.1.e024523.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.186"},{"key":"2025121408025630000_9.1.e024523.3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00281-017-0627-z","article-title":"The role of autoantibodies in the pathophysiology of rheumatoid arthritis","volume":"39","author":"Derksen","year":"2017","journal-title":"Semin Immunopathol"},{"key":"2025121408025630000_9.1.e024523.4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"2025121408025630000_9.1.e024523.5","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.994508"},{"key":"2025121408025630000_9.1.e024523.6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"2025121408025630000_9.1.e024523.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.1"},{"key":"2025121408025630000_9.1.e024523.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"2025121408025630000_9.1.e024523.9","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.003"},{"key":"2025121408025630000_9.1.e024523.10","doi-asserted-by":"publisher","DOI":"10.1038\/nm1763"},{"key":"2025121408025630000_9.1.e024523.11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002539"},{"key":"2025121408025630000_9.1.e024523.12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301555"},{"key":"2025121408025630000_9.1.e024523.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206016"},{"key":"2025121408025630000_9.1.e024523.14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/WNL.0000000000003536","article-title":"Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis","volume":"88","author":"Scheibe","year":"2017","journal-title":"Neurology"},{"key":"2025121408025630000_9.1.e024523.15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/14397595.2018.1432331","article-title":"Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus","volume":"28","author":"Ishii","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2025121408025630000_9.1.e024523.16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.41.5.394"},{"key":"2025121408025630000_9.1.e024523.17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1212\/WNL.30.5.557","article-title":"Humoral immunity in myasthenia gravis: effect of steroids and thymectomy","volume":"30","author":"Tindall","year":"1980","journal-title":"Neurology"},{"key":"2025121408025630000_9.1.e024523.18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1749-6632.1981.tb33739.x","article-title":"Patterns of acetylcholine receptor antibody fluctuation in myasthenia gravis","volume":"377","author":"Seybold","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"2025121408025630000_9.1.e024523.19","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1212\/WNL.33.10.1276","article-title":"Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis","volume":"33","author":"Vincent","year":"1983","journal-title":"Neurology"},{"key":"2025121408025630000_9.1.e024523.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330505"},{"key":"2025121408025630000_9.1.e024523.21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.10.1316"},{"key":"2025121408025630000_9.1.e024523.22","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(83)90096-5"},{"key":"2025121408025630000_9.1.e024523.23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0022-510X(85)90144-3","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 3. The effect of thymectomy","volume":"69","author":"Oosterhuis","year":"1985","journal-title":"J Neurol Sci"},{"key":"2025121408025630000_9.1.e024523.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.038851"},{"key":"2025121408025630000_9.1.e024523.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014647"},{"key":"2025121408025630000_9.1.e024523.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016808"},{"key":"2025121408025630000_9.1.e024523.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01533.x"},{"key":"2025121408025630000_9.1.e024523.28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2149","article-title":"Therapy-related peripheral neuropathy in multiple myeloma patients","volume":"33","author":"Morawska","year":"2015","journal-title":"Hematol Oncol"},{"key":"2025121408025630000_9.1.e024523.29","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23835"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-024523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:03:04Z","timestamp":1765728184000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-024523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,28]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/bmjopen-2018-024523"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-024523","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}